HopeStage
Back to all studies
CompletedNCT02573168

GeneSight Testing to Guide Antipsychotic Treatment

About this titleRead the official source — NCT02573168
Interventional studyAges 18+CanadaSchizophrenia
The study in practice

Understand this study

Who was this study for?

Listed age limits: from 18 years.

Listed locations
TorontoSee all locations and recruitment

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: January 2016
Recruitment status
Completed
Enrollment listed in the registry
103
Sponsor
St. Joseph's Healthcare Hamilton
Sponsor type
Unknown or unclear
Study type
Other
Intervention type
Genetic, Other
Locations
Canada
Age range
Over 18 Years
Official registry ID
NCT02573168
Official title
Show the full official title

A Three-arm, Parallel Group, Multicentre, Double-blind, Randomized Controlled Trial Evaluating the Impact of GeneSight Psychotropic and Enhanced-GeneSight Psychotropic, on Change in Weight Following Antipsychotic Treatment in Patients Suffering From Disorders Indicated for Antipsychotic Utilization

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Toronto

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is St. Joseph's Healthcare Hamilton.

Who was this study for?

Listed age limits: from 18 years.

Want to explore more studies?

Explore studies